Track topics on Twitter Track topics that are important to you
The use of 5-alpha reductase inhibitors (5ARIs) for the treatment of benign prostatic hyperplasia (BPH) and other diseases has been proposed and studied. However, the controversy about its benefits and harms for other diseases has persisted. In this review, we will discuss the newly identified effects of 5ARIs based on recently published studies.
This article was published in the following journal.
Name: Current opinion in urology
To compare the risk of mortality among men treated for benign prostatic hyperplasia (BPH) with 5?-reductase inhibitors (5ARI) to those treated with alpha-blockers (AB) in community practice settings.
To quantify reports made to the Food and Drug Administration Adverse Event Reporting System (FAERS), create a demographic of patient reports, and examine the cluster of symptoms to correlate consisten...
Continued Five-Alpha Reductase Inhibitor Use After Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the Canary Prostate Active Surveillance Study (PASS).
Outcomes of patients who enroll in active surveillance (AS) programs for prostate cancer (PCa) while taking five-alpha reductase inhibitors (5-ARIs) have not been well defined. We sought to determine ...
Vitamin E is a lipid soluble vitamin comprising of eight natural isoforms, namely, α, β, δ, γ isoforms of tocopherol and α, β, δ, γ isoforms of tocotrienol. Many studies have been performed to...
Although combination therapy with 5 alpha-reductase inhibitor (5ARI) and alpha-blocker is one of the standard interventions in symptomatic benign prostatic hyperplasia (BPH), 5ARI monotherapy is seldo...
This retrospective cohort study will assess the association of benign prostatic hyperplasia (BPH) treatment (5-alpha reductase inhibitors (5ARI) and alpha-blocker medications) with the occ...
The enzyme 5-alpha reductase is present in small amounts in muscle and converts testosterone to dihydrotestosterone (DHT). Testosterone affects lean body tissue, muscle size, muscle stren...
It is widely-accepted that serum testosterone level and BMI (body mass index) representative of the degree of obesity has negative correlation. Considering the fact that obesity is being m...
Increased bladder mass occurs as a consequence of bladder outlet obstruction in animals and patients, and relief of bladder outlet obstruction reverses an increased bladder mass. Whether ...
The purpose of this study is to test comprehension of five numeric formats used to present data about treatment benefits and harms.
Drugs that inhibit 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE. They are commonly used to reduce the production of DIHYDROTESTOSTERONE.
Aldo-keto reductase that functions with 5-alpha and 5-beta-steroid reductases to convert steroid hormones into the 3-alpha or 5-alpha and 3-alpha or 5-beta-tetrahydrosteroid, including 5-ALPHA-DIHYDROTESTOSTERONE to ANDROSTANE-3,17-DIOL. It also binds to BILE ACIDS. Mutations in the AKR1C2 gene are associated with Type 8 46, XY DISORDERS OF SEX DEVELOPMENT (SRXY8).
A liver microsomal cytochrome P450 enzyme that catalyzes the 12-alpha-hydroxylation of a broad spectrum of sterols in the presence of molecular oxygen and NADPH-FERRIHEMOPROTEIN REDUCTASE. This enzyme, encoded by CYP8B1gene, converts 7-alpha-hydroxy-4-cholesten-3-one to 7-alpha-12-alpha-dihydroxy-4-cholesten-3-one and is required in the synthesis of BILE ACIDS from cholesterol.
A 1974 Federal act which preempts states' rights with regard to workers' pension benefits and employee benefits. It does not affect the benefits and rights of employees whose employer is self-insured. (From Slee & Slee, Health Care Reform Terms, 1993)
Compounds that inhibit HMG-CoA reductases. They have been shown to directly lower cholesterol synthesis.
Benign Prostatic Hyperplasia (BPH) Erectile Dysfunction Urology Urology is the branch of medicine concerned with the urinary tract and diseases that affect it. Examples include urethritis, urethrostenosis and incontinence. Urology is a su...
Benign Prostatic Hyperplasia (BPH)
An enlarged prostate (benign prostatic enlargement (BPE) or benign prostatic hyperplasia (BPH)) is common in men after the age of about 50. Having an enlarged prostate does not mean you have cancer. In some cases, an enlarged prostate can cause the ...